HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase.

Abstract
Many of the widely used anticancer drugs induce dose-limiting peripheral neuropathies that undermine their therapeutic efficacy. Animal models of chemotherapy-induced painful peripheral neuropathy (CIPN) evoked by a variety of drug classes, including taxanes, vinca alkaloids, platinum-complexes, and proteasome-inhibitors, suggest that the common underlying mechanism in the development of these neuropathies is mitotoxicity in primary nerve sensory axons (PNSAs) arising from reduced mitochondrial bioenergetics [eg adenosine triphosphate (ATP) production deficits due to compromised respiratory complex I and II activity]. The causative mechanisms of this mitotoxicity remain poorly defined. However, peroxynitrite, an important pro-nociceptive agent, has been linked to mitotoxicity in several disease states and may also drive the mitotoxicity associated with CIPN. Our findings reveal that the development of mechano-hypersensitivity induced by paclitaxel, oxaliplatin, and bortezomib was prevented by administration of the peroxynitrite decomposition catalyst Mn(III) 5,10,15,20-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin (MnTE-2-PyP(5+)) without interfering with their anti-tumor effects. Peak CIPN was associated with the nitration and inactivation of superoxide dismutase in the mitochondria, but not in the cytosol, as well as a significant decrease in ATP production within the PNSAs; all of these events were attenuated by MnTE-2-PyP(5+). Our results provide continued support for the role of mitotoxicity in the development of CIPN across chemotherapeutic drug classes, and identify peroxynitrite as a key mediator in these processes, thereby providing the rationale towards development of "peroxynitrite-targeted" therapeutics for CIPN.
AuthorsKali Janes, Timothy Doyle, Leesa Bryant, Emanuela Esposito, Salvatore Cuzzocrea, Jan Ryerse, Gary J Bennett, Daniela Salvemini
JournalPain (Pain) Vol. 154 Issue 11 Pg. 2432-2440 (Nov 2013) ISSN: 1872-6623 [Electronic] United States
PMID23891899 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Boronic Acids
  • Organoplatinum Compounds
  • Pyrazines
  • Oxaliplatin
  • Peroxynitrous Acid
  • Bortezomib
  • Adenosine Triphosphate
  • Superoxide Dismutase
  • Paclitaxel
Topics
  • Adenosine Triphosphate (metabolism)
  • Animals
  • Antineoplastic Agents (adverse effects, pharmacology)
  • Antineoplastic Agents, Phytogenic (pharmacology)
  • Axons (physiology)
  • Boronic Acids (pharmacology)
  • Bortezomib
  • Energy Metabolism (physiology)
  • Hyperalgesia (drug therapy, psychology)
  • Male
  • Mitochondria (drug effects, ultrastructure)
  • Neoplasm Transplantation
  • Neuralgia (chemically induced, metabolism)
  • Organoplatinum Compounds (pharmacology)
  • Oxaliplatin
  • Paclitaxel (pharmacology)
  • Peripheral Nerves (physiology)
  • Peroxynitrous Acid (physiology)
  • Physical Stimulation
  • Protein Processing, Post-Translational (physiology)
  • Pyrazines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Sensory Receptor Cells (physiology)
  • Superoxide Dismutase (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: